Core Insights - The European Commission has approved the label extension for Eylea® 8mg (Aflibercept 8mg) to allow treatment intervals of up to 6 months for two major retinal diseases: neovascular (wet) age-related macular degeneration (nAMD) and vision impairment due to diabetic macular edema (DME) [1] - Eylea® 8mg is the first and only treatment in the EU that offers a treatment interval of up to 6 months for patients with nAMD and DME [1] Company Impact - The approval of Eylea® 8mg represents a significant advancement in the treatment options available for retinal diseases, potentially improving patient adherence and outcomes due to less frequent dosing [1] - This label extension may enhance the competitive positioning of the company within the ophthalmology market, particularly against other VEGF inhibitors [1] Industry Implications - The extension of treatment intervals could lead to increased market share for Eylea® 8mg in the EU, as it addresses a critical need for longer-lasting therapies in the management of nAMD and DME [1] - The approval aligns with broader trends in the pharmaceutical industry towards developing therapies that improve patient convenience and reduce the burden of frequent treatments [1]